KPV is a three-residue peptide, Lys-Pro-Val, corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH). Cell and animal studies report PepT1-dependent uptake in intestinal systems and NF-kB-linked inflammatory-signaling observations, but the record remains preclinical and does not establish a human treatment effect, safety profile, dose, route, or approved therapeutic use.
The most useful way to read KPV research is to keep three layers separate: the sequence relationship to alpha-MSH, what a particular experiment measured, and what remains an inference. That separation matters because a result in an epithelial-cell system, a mouse colitis model, or an engineered delivery platform does not automatically transfer to a person, a different tissue, or a different material.
Apex-specific research boundary: Apex Laboratory materials are research-grade chemical reagents supplied for in-vitro and preclinical research only. They are not pharmaceutical formulations, are not for human consumption, and are not represented here as treatments, administration products, or substitutes for approved medicines.
Regulatory status of KPV: no FDA, EMA, NMPA, MHRA, PMDA, TGA, or Health Canada approval and no marketing authorization anywhere globally, and no approved indication in any jurisdiction. The sources below include no controlled human trial and no approved human dosing protocol.
- KPV is the C-terminal Lys-Pro-Val fragment of the 13-residue alpha-MSH sequence; that relationship is a matter of chemical identity, not proof of an outcome.
- PepT1 uptake and NF-kB-linked observations are best supported in specified intestinal, immune-cell, bronchial-epithelial, and mouse systems.
- Several perturbation studies are consistent with signaling outside classical pigmentary melanocortin-receptor pathways, but they do not establish one exclusive mechanism in every tissue.
- The current source set does not establish controlled human efficacy, general human safety, a dose-response relationship, or a therapeutic protocol.
What Is KPV?
KPV is a defined tripeptide composed of lysine, proline, and valine in that order. The PubChem CID 125672 record maps the substance to formula C16H30N4O4, computed molecular weight 342.43 g/mol, and CAS RN 67727-97-3. Those fields answer an identity question. They do not show how a current lot behaves in an assay or whether an observation transfers beyond the material and model actually tested.
| Field | Record | Interpretation boundary |
|---|---|---|
| Sequence | Lys-Pro-Val (K-P-V) | A defined three-residue chain and alpha-MSH fragment. |
| Parent position | alpha-MSH(11-13) | Sequence relationship; not evidence that every alpha-MSH function is retained. |
| Formula / MW | C16H30N4O4 / 342.43 g/mol | Computed registry fields, not current-lot analytical results. |
| CAS / PubChem | 67727-97-3 / CID 125672 | Registry mapping; not purity, approval, activity, safety, or efficacy. |
How Does KPV Relate to Alpha-MSH?
Alpha-MSH is a 13-residue melanocortin peptide with the sequence SYSMEHFRWGKPV. Cutuli et al. (2000) identify KPV as the carboxy-terminal residues 11-13. That positional relationship is the secure lineage claim: KPV is not merely “related to” alpha-MSH; it is the terminal Lys-Pro-Val segment of the parent sequence.
The functional comparison requires more care. Brzoska et al. (2008) and Brzoska et al. (2010) review evidence that KPV lacks the full melanocortin receptor-binding motif and lacks the pigmentary action associated with the parent hormone in studied systems. Getting et al. (2003) reported that KPV did not increase cAMP in an in-vitro macrophage assay, was not blocked by the MC3/MC4 antagonist SHU9119, and retained an effect in MC1R-nonfunctional mice under the conditions tested.
Those results support a distinction from classical pigmentary melanocortin-receptor signaling. They do not prove that KPV uses no receptor, transporter, or context-dependent partner in every tissue. Earlier immune-system reviews, including Luger et al. (2003) and Luger and Brzoska (2007), are useful maps of the alpha-MSH/KPV literature, but they remain secondary syntheses rather than independent human evidence.
What Mechanisms Have KPV Studies Measured?
PepT1 uptake in intestinal systems
Dalmasso et al. (2008) studied KPV uptake through the di- and tripeptide transporter PepT1 in intestinal epithelial and immune-cell systems. The paper also reported NF-kB and MAP-kinase signaling changes, reduced pro-inflammatory cytokine secretion, and mouse-model observations. PepT1 is therefore a well-supported entry point for the studied gut systems, not a universal transport rule for every organ.
Intracellular signaling in a bronchial-cell model
Land (2012) reported NF-kB, MMP-9, IL-8, and eotaxin changes in human bronchial epithelial cells. The proposed account involved nuclear import, I-kB-alpha stabilization, and reduced p65RelA nuclear translocation. These are direct observations and interpretations in a human-derived cell model. They are not a clinical study and do not establish a whole-body mechanism.
What Does the Intestinal Evidence Show?
The intestinal literature contains several complementary mouse designs. Kannengiesser et al. (2008) reported changes in inflammation, weight loss, histologic infiltrate, and myeloperoxidase activity in DSS and CD45RB-high transfer-colitis models. Retained findings in MC1R-nonfunctional mice were consistent with a mechanism that did not require normal MC1R signaling in those experiments.
Viennois et al. (2016) used a murine colitis-associated-cancer model and reported that the studied KPV effect was present in wild-type mice but absent in PepT1-knockout mice. The knockout contrast strengthens the PepT1-dependence claim for that model. It does not support a statement that KPV prevents cancer in people.
Delivery research asks a different question: can a system concentrate or protect the peptide at a target site? Xiao et al. (2017) studied hyaluronic-acid-functionalized nanoparticles in a mouse colitis model and reported epithelial/macrophage targeting with model-specific inflammatory and mucosal endpoints. The particle design, material properties, and mouse endpoints belong to that engineered platform; they are not instructions for oral use of an unmodified research reagent.
How Should the Wider KPV Literature Be Read?
KPV research is not confined to intestinal models. The bronchial epithelial-cell study above extends the NF-kB discussion to a different cell system, while Cutuli et al. (2000) reported in-vitro antimicrobial observations for alpha-MSH peptides and KPV against the organisms tested. Neither line of work establishes a therapeutic airway, skin, infection, or antimicrobial use.
Form also matters. Songok et al. (2018) examined reductive glycoalkylation of the lysine residue and reported improved proteolytic stability for selected modified analogs. The study also helps explain why findings for one KPV form cannot be assigned automatically to another: chemical modification can change stability and assay behavior. An analog result is not a shelf-life claim for an unmodified lot.
How Strong Is the KPV Evidence?
The evidence is strongest for chemical lineage and for particular cell and mouse observations. It becomes weaker when the question moves from “what happened in this system?” to “what happens in another tissue, species, formulation, or person?” Reviews can connect findings across the field, but they cannot close those experimental gaps.
| Layer | What the selected record can support | What remains unresolved |
|---|---|---|
| Identity | Sequence, alpha-MSH position, and registry fields. | Lot purity, activity, stability, sterility, or biological outcome. |
| Cells | Transport and signaling observations in specified epithelial and immune systems. | Whole-organism exposure, general mechanism, or clinical effect. |
| Mouse models | Inflammatory, histologic, transporter-knockout, and delivery-system findings under named designs. | Human efficacy, human safety, or transfer to a different material. |
| Controlled human studies | No robust controlled record in this source set. | Efficacy, dose-response, pharmacokinetics, long-term safety, and rare risks. |
Reported findings by study
| Study | System (species / model) | Reported result | Source |
|---|---|---|---|
| Cutuli 2000 | S. aureus and C. albicans, in vitro | KPV and alpha-MSH inhibited colony and germ-tube formation over a broad range including picomolar; no quantitative endpoint reported. | PMID 10670585 |
| Getting 2003 | Crystal-induced peritonitis, mouse; macrophage activation, in vitro | Significantly fewer peritoneal neutrophils, unblocked by SHU9119; in the in-vitro macrophage assay KPV failed to increase cAMP; no quantitative endpoint reported. | PMID 12750433 |
| Luger 2003 | Narrative review, immune system | Synthesis of alpha-MSH cytokine and NF-kB effects; no quantitative endpoint reported. | PMID 12851308 |
| Luger and Brzoska 2007 | Narrative review | Attributes most alpha-MSH anti-inflammatory activity to the C-terminal KPV motif; no quantitative endpoint reported. | PMID 17934097 |
| Dalmasso 2008 | Human intestinal epithelial and Jurkat cells; DSS and TNBS colitis, mouse | Nanomolar KPV suppressed NF-kB and MAP-kinase activation and cytokine output; oral KPV lowered DSS and TNBS colitis incidence. No quantitative endpoint reported. | PMID 18061177 |
| Kannengiesser 2008 | DSS and CD45RB-high transfer colitis, mouse | Greater weight regain, less histologic infiltrate, significantly lower colonic myeloperoxidase; all MC1R-nonfunctional mice given KPV survived. No quantitative endpoint reported. | PMID 18092346 |
| Brzoska 2008 | Narrative review | KPV keeps the anti-inflammatory effect without the pigmentary action; no quantitative endpoint reported. | PMID 18612139 |
| Brzoska 2010 | Narrative review | KPV lacks the motif needed to bind any known melanocortin receptor; no quantitative endpoint reported. | PMID 21222263 |
| Land 2012 | 16HBE14o- human bronchial epithelial cells, in vitro | Dose-dependent fall in NF-kB reporter activity, MMP-9, IL-8 and eotaxin, with p65RelA nuclear import blocked; no quantitative endpoint reported. | PMID 22837805 |
| Viennois 2016 | AOM/DSS colitis-associated cancer; wild-type and PepT1-knockout mouse | Prevented carcinogenesis in wild-type mice, no such effect in PepT1-knockout mice; no quantitative endpoint reported. | PMID 27458604 |
| Xiao 2017 | HA-functionalized KPV nanoparticles as synthesized; hydrogel-encapsulated dosing in ulcerative-colitis mouse | As-synthesized particles about 272.3 nm, zeta potential near -5.3 mV before hydrogel encapsulation; in hydrogel the HA-functionalized particles downregulated TNF-alpha and limited mucosal damage more than non-HA KPV nanoparticles. | PMID 28143741 |
| Songok 2018 | Glycoalkylated KPV analogs, in vitro | No antimicrobial activity for Ac-KPV-NH2 or the analogs; the analogs gained protease stability. No quantitative endpoint reported. | PMID 29953505 |
What Can Analytical Documentation Verify?
A defensible KPV experiment connects literature evidence to material evidence without confusing the two. The protocol should name the intended sequence and form. The lot record should be traceable. HPLC and mass spectrometry should be interpreted only within the questions their methods can answer.
- Identity fields: sequence, formula, molecular weight, form, and registry mapping should agree across the protocol and lot documentation. The lot COA, not this guide, records the purity and identity results for any given batch.
- HPLC: a chromatographic profile and reported peak-area purity depend on the method, detector, integration, and system suitability. The guide to HPLC testing for peptide purity explains why HPLC does not establish molecular identity, total content, sterility, or activity by itself.
- Mass spectrometry: a mass result can support analyte identity, but a matching mass alone does not establish purity, sequence position, sterility, or efficacy.
- Traceability: lot, date, method, result, laboratory, and document identifiers should match. See how to read a peptide COA for the field-level review framework.
- Experimental fit: controls, solvent system, concentration range, handling, and acceptance criteria belong to the approved institutional protocol.
The current KPV product record is the separate destination for live commercial and lot-specific information. Price, stock, variants, shipping, current-batch results, and product specifications are intentionally not cached in this evergreen guide and require same-day first-party verification. General material-handling principles are covered separately in the peptide storage guide.
Frequently Asked Questions
What is the KPV peptide?
KPV is the three-residue peptide Lys-Pro-Val. It corresponds to residues 11-13 at the C-terminus of alpha-MSH. PubChem maps it to CID 125672, formula C16H30N4O4, computed molecular weight 342.43 g/mol, and CAS RN 67727-97-3. Those fields establish identity, not biological activity, safety, efficacy, or approval.
Does KPV use melanocortin receptors?
Several preclinical experiments are consistent with signaling outside classical melanocortin-receptor pathways: KPV did not raise cAMP, was not blocked by one MC3/MC4 antagonist, and retained an effect in MC1R-nonfunctional mice under the tested conditions. That evidence does not prove that no receptor, transporter, or context-dependent partner contributes in every tissue.
What is PepT1’s role in KPV research?
PepT1 is a di- and tripeptide transporter. KPV uptake through PepT1 was reported in intestinal epithelial and immune-cell systems, and a mouse knockout experiment supported PepT1 dependence in a colitis-associated-cancer model. This is strongest as a gut-system finding and should not be generalized to every tissue.
Has KPV been proven effective in people?
No robust controlled human efficacy record is established in the selected source set. The cited evidence consists primarily of biochemical identity, cultured-cell experiments, mouse intestinal models, engineered delivery systems, and modified-analog studies. Those layers do not establish a human treatment effect, dose-response relationship, safety profile, or therapeutic protocol.
What can HPLC and mass spectrometry show for KPV?
HPLC can characterize a sample’s chromatographic profile and estimate purity under a stated method. Mass spectrometry can support molecular-mass identity. Neither method alone establishes sequence position, total content, sterility, endotoxin status, biological activity, human safety, or efficacy; both belong in a lot-matched analytical and experimental record.
Research Use Disclaimer
This article is provided for educational and research reference purposes only. KPV and all products sold by Apex Laboratory are intended exclusively for in-vitro and preclinical laboratory research and are not for human consumption, veterinary use, diagnosis, treatment, or administration. Researchers should consult the cited primary literature, current institutional SOPs, and lot-specific analytical records for complete methods and limitations.
